Clinical Trials Logo

Filter by:
NCT ID: NCT04984057 Recruiting - Clinical trials for Bronchopulmonary Dysplasia

Optimal Dose of Surfactant for Preterm Infants With Respiratory Distress Syndrome

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

In preterm infants with neonatal respiratory distress syndrome (RDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal incidences of bronchopulmonary dysplasia(BPD) and/or death. But not all preterm infants with RDS can be beneficial. Otherwise, the international neonatal acute RDS (NARDS) collaborative group provides the first consensus definition for NARDS in 2017. And whether or not PS being beneficial in preterm infants with NARDS remains unknown.

NCT ID: NCT04984005 Recruiting - Obesity Clinical Trials

The Interaction and Regulation Mechanism of Different Exercise Patterns With Metabolic Syndrome and Related Metabolic Diseases

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

In order to obtain suitable exercise intervention model for children and adolescents with obese or metabolic syndrome in China, we conduct a RCT to examine the effects of different intensity exercise intervention on weight, and other cardiometabolic risk factors among children and adolescents, we also test the effects of exercise interventions on multi-omics such as metabolomics, gut microbiome, genetics, and explore the potential mechanisms by which exercise interventions modulate cardiometabolic risk. This is a randomized controlled study. Children and adolescents with obesity or metabolic syndrome were randomly divided into three groups, including low intensity exercise training group, moderate and intermittent high intensity exercise training group. The investigators will obtain organ hydrodynamics indexes by abdominal ultrasound and computational fluid dynamics technology, and obtain the metabolic regulation mechanism of the body in response to exercise through the detection of metabolism related small molecules in blood and urine and the analysis of intestinal flora, so as to explore the potential value and mechanism of different exercise modes in the treatment of obesity and metabolic syndrome. At the same time, the behavior and self-consciousness of children and adolescents will be investigated to obtain the suitable exercise intervention model for Chinese children and adolescents with obesity and metabolic syndrome. In conclusion, this study aims to demonstrate which exercise mode can alleviate obesity or reverse metabolic diseases, analyze which factors can sense exercise, and explore the potential mechanisms through mutil-omic approach, so as to improve metabolic syndrome.

NCT ID: NCT04983706 Recruiting - Prostate Cancer Clinical Trials

Optimization of the Core Number and Location for Targeted Prostate Biopsy

Start date: July 5, 2021
Phase: N/A
Study type: Interventional

This study aims to investigate the effect of core number and location optimization for targeted prostate biopsy on pathological accuracy.

NCT ID: NCT04983121 Recruiting - Breast Neoplasms Clinical Trials

Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients

Start date: August 1, 2021
Phase: Phase 2
Study type: Interventional

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) is an antibody-conjugated drug. Results from the phase I safety, tolerability and pharmacokinetic trial of ARX788 single drug in Chinese patients with advanced HER2 breast cancer indicated a good safety of the test drug, and responses to anti-tumor therapy were observed in the target dose group. Phase II clinical trial is being carried out gradually. This trial is designed to observe the effectiveness and safety of pyrotinib maleate combined with ARX788 neoadjuvant treatment in stage II-III HER2-positive breast cancer patients experiencing a poor efficacy of trastuzumab and pertuzumab.

NCT ID: NCT04983043 Recruiting - Clinical trials for Chronic Heart Failure With Reduced Ejection Fraction

Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure

Start date: June 10, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety and the best effective dose of QiShen YiQi Dripping Pills in the treatment of chronic heart failure with decreased ejection fraction of CHD (Qi deficiency and blood stasis syndrome).

NCT ID: NCT04982939 Recruiting - Gastric Cancer Clinical Trials

Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer

Start date: June 21, 2021
Phase: Phase 2
Study type: Interventional

To evaluate efficacy and safety of peri-operative sintilimab in combination with SOX in resectable locally advanced gastric or gastroesophageal junction adenocarcinoma

NCT ID: NCT04982900 Recruiting - Clinical trials for Multiple Primary Lung Cancers

Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities

TERMGGO
Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

This study is a multi-center, prospective, double-blind randomized controlled clinical trial. The purpose is to evaluate the efficacy and safety of EGFR-TKI on residual GGOs after surgery in patients with multiple primary lung cancers with ground glass nodules. This study is expected to prove that compared with placebo in the control group, EGFR-TKI can significantly reduce the residual GGOs lesions in patients with EGFR-positive multiple primary lung cancers with ground-glass opacity, and bring a higher objective response rate (ORR), thus provides new insights for treatment of these patients.

NCT ID: NCT04982549 Recruiting - Clinical trials for Unresectable Stage III NSCLC

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Start date: January 21, 2021
Phase: Phase 2
Study type: Interventional

This is a prospective, multi-center, single arm study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + SoC CRT) in patients with locally advanced, unresectable NSCLC (Stage III).

NCT ID: NCT04982367 Recruiting - Clinical trials for Peripheral Artery Disease

Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis

Start date: December 8, 2021
Phase: N/A
Study type: Interventional

A prospective randomized trial designed to compare the efficacy and safety of Sirolimus coated balloon (SCB) versus paclitaxel coated balloon (DCB) in the treatment of femoropopliteal artery stenosis

NCT ID: NCT04982276 Recruiting - Clinical trials for Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Start date: July 13, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma .